SKIN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

77.56M

-7.11%

0.010

-150%

69.45M

-0.22%

-0.030

-175%

79.23M

+1.31%

0.020

-90.83%

Estimates Revision

The market is revising Upward the revenue expectations for The Beauty Health Company (SKIN) for FY2025, with the revenue forecasts being adjusted by 0.69% over the past three months. During the same period, the stock price has changed by -42.98%.

Revenue Estimates for FY2025

Revise Upward

+0.69%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-313.33%

In Past 3 Month

Stock Price

Go Down

-42.98%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast SKIN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SKIN is 2.13 USD with a low forecast of 1.50 USD and a high forecast of 3.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

4 Hold

0 Sell

Hold

Current: 1.380

Low

1.50

Averages

2.13

High

3.50

Current: 1.380

Low

1.50

Averages

2.13

High

3.50

TD Cowen

Oliver Chen

Hold

maintain

2025-09-22

Reason

TD Cowen

Oliver Chen

Price Target

2025-09-22

maintain

Hold

Reason

TD Cowen analyst Oliver Chen raised the firm's price target on Beauty Health to $2.50 from $2 and keeps a Hold rating on the shares. The firm believes the CEO's reset is working on managing device sales (30%) churn and fostering consumables innovation (70%), along with deeper provider engagement in its 35k installed base.

Roth Capital

George Kelly

Buy

initiated

$3.50

2025-09-19

Reason

Roth Capital

George Kelly

Price Target

$3.50

2025-09-19

initiated

Buy

Reason

Roth Capital analyst George Kelly initiated coverage of Beauty Health with a Buy rating and $3.50 price target. The firm is positive on the company's turnaround efforts and believes consensus estimates are too low given the opportunity for more cost-cutting. Further, Beauty Health's growth can improve with the launch of new products in the second half of 2025 and 2026, the analyst tells investors in a research note.

TD Cowen

Oliver Chen

Hold

maintain

2025-05-12

Reason

TD Cowen

Oliver Chen

Price Target

2025-05-12

maintain

Hold

Reason

TD Cowen analyst Oliver Chen raised the firm's price target on Beauty Health to $2 from $1.50 and keeps a Hold rating on the shares. The firm noted Q1 sales declined but management is cautious due to macro and lowered expectations for the remainder of FY25.Cowen views the updated FY25 guide as conservative, but APAC and tariffs remain key pressure points.

Canaccord Genuity

Susan Anderson

Hold

Maintains

$1.75 → $1.5

2025-03-13

Reason

Canaccord Genuity

Susan Anderson

Price Target

$1.75 → $1.5

2025-03-13

Maintains

Hold

Reason

Canaccord lowered the firm's price target on Beauty Health to $1.50 from $1.75 and keeps a Hold rating on the shares. The firm said they reported Q4 sales were lower and although the high- margin consumables business continues to perform well, we continue to see new machine placements severely pressured due to macro conditions.

Valuation Metrics

The current forward P/E ratio for Beauty Health Co (SKIN.O) is 8.95, compared to its 5-year average forward P/E of 48.26. For a more detailed relative valuation and DCF analysis to assess Beauty Health Co 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

48.26

Current PE

8.95

Overvalued PE

230.43

Undervalued PE

-133.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

36.73

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

81.48

Undervalued EV/EBITDA

-8.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.53

Current PS

0.00

Overvalued PS

7.15

Undervalued PS

-0.09

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 87233.33% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SKIN News & Events

Events Timeline

No data

News

7.5

12-04Globenewswire

Beauty Health Releases 2025 Skintuition Report, 75% Consumers Prioritize Skin Quality

7.0

11-30PRnewswire

Halper Sadeh Investigates Beauty Health (SKIN) for Potential Fiduciary Breaches

9.5

11-07NASDAQ.COM

After-Hours Surge in GMED, TNDM, ICUI, ORGO, SKIN, TXG Fueled by Q3 Results

People Also Watch

Frequently Asked Questions

What is Beauty Health Co (SKIN) stock price today?

The current price of SKIN is 1.38 USD — it has decreased -1.43 % in the last trading day.

What is Beauty Health Co (SKIN)'s business?

The Beauty Health Company is a medical technology meets beauty company that delivers skin-health experiences. The Company and its subsidiaries design, develop, manufacture, market, and sell esthetic technologies and products. It specializes in skin health for all ages, genders, skin tones, and skin types. Its brands include Hydrafacial, SkinStylus, and Keravive. Hydrafacial created the category of hydradermabrasion with its patented delivery system that cleanses, extracts, and hydrates the skin with proprietary solutions and serums. SkinStylus specializes in nanoneedling and microneedling, where its products are designed to provide either a non-invasive (nanoneedling) or minimally invasive (microneedling) skin treatment to individuals. Keravive specializes in scalp health with its products that are designed to support the hair’s natural growth by cleansing, exfoliating, and hydrating the scalp and hair follicles.

What is the price predicton of SKIN Stock?

What is Beauty Health Co (SKIN)'s revenue for the last quarter?

Beauty Health Co revenue for the last quarter amounts to 70.66M USD, decreased -10.34 % YoY.

What is Beauty Health Co (SKIN)'s earnings per share (EPS) for the last quarter?

Beauty Health Co. EPS for the last quarter amounts to -0.09 USD, decreased -40.00 % YoY.

What changes have occurred in the market's expectations for Beauty Health Co (SKIN)'s fundamentals?

How many employees does Beauty Health Co (SKIN). have?

Beauty Health Co (SKIN) has 769 emplpoyees as of December 16 2025.

What is Beauty Health Co (SKIN) market cap?

Today SKIN has the market capitalization of 175.95M USD.